https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-10-01 / Brain Pathol. 2009 Oct;19(4):694-712
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-10-01 / Brain Pathol. 2009 Oct;19(4):694-7122009-10-01 00:00:002021-11-15 14:46:05Dendritic cell therapy of high-grade gliomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-09-01 / J BUON 2009 Sep;14 Suppl 1:S111-22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-09-01 / J BUON 2009 Sep;14 Suppl 1:S111-222009-09-01 00:00:002021-11-15 17:00:58Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-06-10 / J. Virol. 2009 Aug;83(16):8108-21
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-06-10 / J. Virol. 2009 Aug;83(16):8108-212009-06-10 00:00:002021-11-15 17:01:25Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):971-82
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):971-822009-04-01 00:00:002021-11-15 17:01:56Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):951-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):951-622009-04-01 00:00:002021-11-15 17:02:15Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-01-30 / Eur. Urol. 2009 Jun;55(6):1333-42
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-01-30 / Eur. Urol. 2009 Jun;55(6):1333-422009-01-30 00:00:002021-11-15 14:46:31Vaccine therapy in patients with renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-01-01 / Methods Mol. Biol. 2009;542:565-605
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-01-01 / Methods Mol. Biol. 2009;542:565-6052009-01-01 00:00:002021-11-15 17:03:01Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-01-01 / Expert Rev Vaccines 2009 Jan;8(1):51-66
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-01-01 / Expert Rev Vaccines 2009 Jan;8(1):51-662009-01-01 00:00:002021-11-15 17:02:36Randomized clinical studies of anti-tumor vaccination: state of the art in 2008
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-11-08 / Cancer Immunol. Immunother. 2009 Jun;58(6):887-900
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-11-08 / Cancer Immunol. Immunother. 2009 Jun;58(6):887-9002008-11-08 00:00:002021-11-15 17:03:25Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-10-01 / Int. J. Oncol. 2008 Oct;33(4):823-32
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-10-01 / Int. J. Oncol. 2008 Oct;33(4):823-322008-10-01 00:00:002021-11-15 17:03:44Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2
